Decision: Favourable
Study Title:
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients with Relapsed Refractory Multiple Myeloma
NREC Code:
22-NREC-CT-109
Decision:
Favourable
Meeting Date:
22/06/2022
Study Type:
CT application
Principal Investigator:
Dr Kamal Fadalla
PI Institution:
St Vincent's University Hospital
Sponsor:
Takeda Development Center Americas, Inc.